Novavax Plays Down EU COVID Vaccine Contract Delay
Manufacturing Issues Not To Blame
Executive Summary
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.
You may also be interested in...
COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic
AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.
Next EU COVID-19 Vaccine Contracts Will Take On ‘Lessons Learned’ In Capacity And Supply
The European Commission appears to be favoring mRNA vaccines in its negotiations with companies on the next generation of COVID-19 vaccine contracts. Manufacturing finally appears to be gaining momentum, and the health commissioner claims the EU has “turned the corner” with its vaccination programs.
UK Government Plays Matchmaker In GSK/Novavax Deal To ‘Onshore’ COVID-19 Vaccine Production
The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance